Sirio Pharma Co., Ltd. (SHE:300791)
China · Delayed Price · Currency is CNY 18.10
+0.97 (5.66%)
May 29, 2026, 3:04 PM CST
Sirio Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,295 | 4,246 | 4,184 | 3,568 | 2,493 | 2,331 |
Other Revenue | 16.69 | 16.69 | 27.4 | 13.91 | 14.19 | 38.01 |
| 4,312 | 4,263 | 4,211 | 3,582 | 2,507 | 2,369 | |
Revenue Growth (YoY) | 2.33% | 1.23% | 17.56% | 42.87% | 5.84% | 14.62% |
Cost of Revenue | 3,083 | 3,043 | 2,891 | 2,498 | 1,737 | 1,604 |
Gross Profit | 1,229 | 1,220 | 1,320 | 1,085 | 770.42 | 764.94 |
Selling, General & Admin | 831.58 | 839.29 | 770.86 | 628.44 | 428.27 | 385.27 |
Research & Development | 146.95 | 145.94 | 125.94 | 110.49 | 80.72 | 83.19 |
Other Operating Expenses | 22.07 | 20.41 | 25.94 | -35.8 | 14.85 | 14.4 |
Operating Expenses | 1,010 | 1,010 | 923.06 | 708.19 | 527.83 | 483.83 |
Operating Income | 219.09 | 209.97 | 396.78 | 376.33 | 242.59 | 281.11 |
Interest Expense | -97.51 | -102.73 | -95.03 | -78.48 | -42.77 | -13.93 |
Interest & Investment Income | 6.94 | 8.39 | 6.89 | 9.24 | 34.97 | 32.18 |
Currency Exchange Gain (Loss) | -6.34 | -6.34 | 10.86 | 20.31 | 25.49 | -18.17 |
Other Non Operating Income (Expenses) | -22.42 | -2.9 | -2.87 | -1.28 | -1.47 | -1.25 |
EBT Excluding Unusual Items | 99.76 | 106.39 | 316.63 | 326.11 | 258.81 | 279.96 |
Gain (Loss) on Sale of Investments | -5.26 | -0.53 | -26.72 | -57.67 | -1.64 | -1.05 |
Gain (Loss) on Sale of Assets | 1.4 | 2.42 | 0.24 | 0.03 | -5.51 | 0.15 |
Asset Writedown | -138.38 | -137.18 | -4.41 | -0.95 | - | -1.86 |
Other Unusual Items | 23.52 | 23.01 | 30.91 | 5.73 | -0.15 | 3.7 |
Pretax Income | -18.97 | -5.89 | 316.65 | 273.26 | 251.52 | 280.9 |
Income Tax Expense | -24.81 | -26.29 | 34.64 | 32.97 | 39.23 | 49.07 |
Earnings From Continuing Operations | 5.84 | 20.4 | 282.02 | 240.29 | 212.29 | 231.83 |
Minority Interest in Earnings | 111.95 | 116.13 | 43.04 | 40.75 | - | - |
Net Income | 117.8 | 136.53 | 325.06 | 281.04 | 212.29 | 231.83 |
Net Income to Common | 117.8 | 136.53 | 325.06 | 281.04 | 212.29 | 231.83 |
Net Income Growth | -64.38% | -58.00% | 15.66% | 32.39% | -8.43% | -9.92% |
Shares Outstanding (Basic) | 306 | 306 | 304 | 305 | 304 | 304 |
Shares Outstanding (Diluted) | 306 | 306 | 304 | 305 | 307 | 322 |
Shares Change (YoY) | 0.77% | 0.63% | -0.36% | -0.82% | -4.47% | 5.00% |
EPS (Basic) | 0.39 | 0.45 | 1.07 | 0.92 | 0.70 | 0.76 |
EPS (Diluted) | 0.39 | 0.45 | 1.07 | 0.92 | 0.69 | 0.72 |
EPS Growth | -64.65% | -58.26% | 16.08% | 33.48% | -4.15% | -14.21% |
Free Cash Flow | 38.84 | 128.92 | 154.84 | -65.62 | 151.17 | -183.31 |
Free Cash Flow Per Share | 0.13 | 0.42 | 0.51 | -0.21 | 0.49 | -0.57 |
Dividend Per Share | 0.130 | 0.130 | 0.500 | 0.651 | 0.207 | 0.237 |
Dividend Growth | -74.00% | -74.00% | -23.18% | 214.29% | -12.50% | - |
Gross Margin | 28.50% | 28.62% | 31.34% | 30.28% | 30.73% | 32.29% |
Operating Margin | 5.08% | 4.92% | 9.42% | 10.51% | 9.68% | 11.87% |
Profit Margin | 2.73% | 3.20% | 7.72% | 7.85% | 8.47% | 9.79% |
Free Cash Flow Margin | 0.90% | 3.02% | 3.68% | -1.83% | 6.03% | -7.74% |
EBITDA | - | 401.8 | 601.12 | 597.06 | 366.95 | 379.29 |
EBITDA Margin | - | 9.43% | 14.27% | 16.67% | 14.64% | 16.01% |
D&A For EBITDA | - | 191.84 | 204.33 | 220.73 | 124.36 | 98.18 |
EBIT | 219.09 | 209.97 | 396.78 | 376.33 | 242.59 | 281.11 |
EBIT Margin | 5.08% | 4.92% | 9.42% | 10.51% | 9.68% | 11.87% |
Effective Tax Rate | - | - | 10.94% | 12.06% | 15.60% | 17.47% |
Revenue as Reported | 4,312 | 4,263 | 4,211 | 3,582 | 2,507 | 2,369 |
Advertising Expenses | - | 10.76 | 12.17 | 7.8 | 11.73 | 31.9 |